Triamcinolone-induced intraocular pressure elevation: intravitreal injection for macular edema and posterior subtenon injection for uveitis.
OBJECTIVE
To assess the effect of intravitreal and posterior subtenon injections of triamcinolone acetonide (TA) on intraocular pressure (IOP).


METHODS
we reviewed 42 consecutive eyes after intravitreal TA injection (IVTA) and 43 eyes following posterior subtenon TA injection (PSTA). All cases had a minimum follow-up time of three months. After injection, the value and time of the maximal IOP, the amount of IOP elevation and the needs of the medication were assessed.


RESULTS
The lOP increased significantly (p < 0.001) from 16.3 +/- 2.5 mmHg preoperatively to a mean maximum of 21.7 +/- 5.3 mmHg in the IVTA group, and from 15.3 +/- 4.5 mmHg to 20.6 +/- 3.0 mmHg in the PSTA group. An elevation in the IOP of more than 5 mmHg from the baseline lOP was seen in 52.4% of the IVTA group at a mean time of 3.1 weeks postoperatively, and 44.2% of the PSTA group displayed an IOP elevation at 5.9 weeks.


CONCLUSIONS
Both developed significant elevations of IOP, but this appeared at a later date in the PSTA group. Careful follow-up after local injection of steroids is necessary.
Jea
Seung Youn
SY
Department of Ophthalmology, College of Medicine, Pusan National University, Busan, Korea. jea-sy@hanmail.net
Byon
Ik Soo
IS
Oum
Boo Sup
BS
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects*; D008269:Macular Edema / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000139:chemically induced* / Q000503:physiopathology; D009915:Orbit; D012189:Retrospective Studies; D013997:Time Factors; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects*; D015866:Uveitis, Posterior / Q000188:drug therapy* / Q000473:pathology; D014822:Vitreous Body
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide